← Human Trials & Peer-Reviewed Studies
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial
Plain-language guide to PMID 18374840 (2008): parallel-group randomized controlled trial study of Insulin Glargine and Insulin Lispro in 418 patients.
Key Facts
- PMID
- 18374840
- Journal
- Lancet (London, England)
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Bretzel RG et al. (6 authors)
- DOI
- 10.1016/S0140-6736(08)60485-7
- Registered trial
- NCT00311818
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Glargine and Insulin Lispro in this randomized controlled trial publication.
The primary objective was to compare the change in haemoglobin A(1c) from baseline to endpoint (week 44) between the two regimens.
Why It Was Studied
As type 2 diabetes mellitus progresses, oral hypoglycaemic agents often fail to maintain blood glucose control and insulin is needed.
Who Took Part
According to the abstract, 418 patients were involved.
The age groups tagged for this paper are middle-aged adults, both men and women.
In the 44-week, parallel, open study that was undertaken in 69 study sites across Europe and Australia, 418 patients with type 2 diabetes mellitus that was inadequately controlled by oral hypoglycaemic agents were randomly assigned to either insulin glargine taken once daily at the same time every day or to insulin lispro administered three times per day.
How the Study Was Run
The researchers set it up as a randomized and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.
The Insulin Glargine group and the comparison group ran side by side rather than switching.
Randomisation was done with a central randomisation service.
This study is registered with ClinicalTrials.gov, number NCT00311818.
What Was Measured
The subject headings attached to it are Australia, Blood Glucose, Diabetes Mellitus, Type 2, Europe, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.
What This Means in Plain Language
The paper is a randomized and parallel-group study of Insulin Glargine and Insulin Lispro in 418 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (Lancet (London, England)), a journal based in England.
More context: the Insulin Glargine compound page and the Insulin Lispro compound page.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Insulin Lispro: A rapid-acting mealtime insulin analog; brands include Humalog, Admelog and Lyumjev.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.